LBCTR2020021295已完成2 期
A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of VIT-2763 in Subjects with Non-transfusion Dependent Beta-thalassaemia
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 12 至 65（—）
- 性别
- All
入选标准
- •1.Documented diagnosis of NTDT, including a ß-thalassaemia intermedia-phenotype.
- •2.NTDT is defined as subjects having received <5 units of red blood cells (RBCs) during the 24-week period prior to randomisation/first drug administration of VIT-2763 or placebo (Day 1; 1 unit is defined as 200 to 350 ml of transfused packed RBCs and last RBC transfusion must have been received =14 days prior to randomisation).
- •Note: Subjects who are supposed to receive RBC transfusions after randomisation in the Investigator’s opinion, and according to local practise, and having received at least 1 dose of VIT-2763, may be considered to stay on study treatment for safety reasons, and in case there are no tolerability concerns. Subjects will be censored for secondary efficacy.
- •3.Male and female adult NTDT subjects, 18-65 years of age inclusive (Cohort I only) at time of screening.
- •4.Male and female adolescent NTDT subjects, 12-17 years of age inclusive (Cohort II only) at time of screening.
- •5.Subjects must have a mean baseline Hb =11 g/dl, based on 2 consecutive measurements =1 week apart within 6 weeks prior to randomisation/baseline, and obtained Hb values show less than 10% relative difference (and equal or less than 1.0 g/dl absolute change between the highest and lowest value) between at least 2 measurements.
- •Note: If there is 1 retrospective Hb value available for the subject at maximum of 2 weeks prior to screening (Day -28), the Hb value can be taken into consideration. A subject not meeting this criterion would be excluded but can be rescreened at maximum 2 times at a later time point.
排除标准
- •1.Documented diagnosis of transfusion dependent thalassaemia (TDT), including a beta-thalassaemia major phenotype (including ß0/ß0, ß+/ß+, ß0/ß+ genotype), and mixed compound heterozygous for sickling phenotype variants such as Hb S/ß-thalassaemia, or transfusion dependent non-deletional Hb H disease (i.e., Hb constant spring) or Hb C disease.
- •2.Subjects on concomitant iron chelation therapy (ICT) or subjects on prior ICT when discontinued less than 4 weeks prior randomisation. Note: If ICT was discontinued =4 weeks prior randomisation the subject is eligible.
- •3.ICT naïve subjects with serum ferritin <150 ng/ml and documented LIC =1 mg/g liver dry weight assessed through MRI, or subjects on prior ICT with serum ferritin <300 ng/ml and documented LIC <3 mg/g liver dry weight assessed through MRI.
- •4.Subjects with TSAT <30%.
- •5.Subjects with documented LIC >15 mg/g liver dry weight assessed through MRI, or a documented myocardial T2-star (T2*) <20 ms.
- •6.Adult or adolescent subjects with body weight <40.0 kg or >100 kg at screening and/or randomisation.
- •7.Chronic liver disease and/or alanine transaminase (ALT), aspartate transaminase (AST) or gamma-glutamyl transpeptidase (GGT) above 3-fold the upper limit of normal (ULN) range at screening.
- •Note: A subject fulfilling this criterion will be excluded but can be rescreened
- •at a later time point (in order to fulfil eligibility, =2 values within =1 week
- •should be assessed and be within eligibility limits).
- •8.Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2 (according to chronic kidney disease classification Stage 4 or higher), and/or significant albuminuria >30 mg/mmol. eGFR should be estimated according to Cockcroft-Gault.
- •9.Newly diagnosed folate deficiency anaemia and/or Vitamin B12 megaloblastic anaemia. Subjects with known folate deficiency anaemia and/or Vitamin B12 megaloblastic anaemia who are on =12 weeks stable replacement therapy are eligible.
- •Note: A subject fulfilling this criterion will be excluded but can be rescreened
- •at a later time point.
- •10.Any history or clinically important finding of cardiac disorders, such as clinically relevant cardiac arrhythmia, cardiomyopathy, coronary disease, valve disorder, or heart failure according to New York Heart Association classification 3-4.
- •11.Subjects with partial or total splenectomy.
研究者
相似试验
进行中（未招募）
1 期
A study to the assess safety, tolerability and the effect of VIT-2763 on blood markers, symptoms and quality of life in patients with non-transfusion dependent beta-thalassemiaon-transfusion Dependent Beta-thalassaemia.MedDRA version: 20.0Level: LLTClassification code 10074355Term: Non-transfusion dependent thalassaemiaSystem Organ Class: 100000004850EUCTR2019-002221-29-GRVifor (International) Inc.36
进行中（未招募）
1 期
A study to the assess safety, tolerability and the effect of VIT-2763 on blood markers, symptoms and quality of life in patients with non-transfusion dependent beta-thalassemiaEUCTR2019-002221-29-ITVIFOR (INTERNATIONAL) INC.25
已完成
2 期
Study to assess the safety and effectiveness of propagermanium as add-on therapy in FSGS patients who are already taking Irbesartan.Focal Segmental GlomerulosclerosisACTRN12618000910202Dimerix Ltd8
招募中
1 期
MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF)CTIS2023-505919-21-00Bristol-Myers Squibb Services Unlimited Company55
进行中（未招募）
1 期
Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)MedDRA version: 20.0 Level: LLT Classification code 10071166 Term: Bladder pain syndrome System Organ Class: 100000004857EUCTR2016-004138-12-BEAstellas Pharma Europe B.V.163